New 14‑day postpartum depression pill costs about US$16,000 and acts within days, reports say
Jennifer Lawrence says an oral postpartum depression drug helped ease her symptoms — and that same medication, Zurzuvae, is now heading to Canada with a price tag of about US$16,000 for a 14‑day course.
Health Canada has approved zuranolone, marketed as Zurzuvae, as the first drug specifically designed to treat postpartum depression and the first oral option in this space, as per The Canadian Press,
The pill is taken once daily in the evening with a fatty meal for 14 days at a 50 mg dose, and some women in trials improved within three days, the FDA said.
Why this matters for plans
Postpartum depression affects one in five women during or after pregnancy, according to Health Canada’s website, as reported by The Canadian Press.
“When close to 50 percent of the workforce is impacted by the gender health gap and don’t have the support they need and deserve, we see an impact on workplaces,” said Swati Matta, head of women’s health at Dialogue, in an interview with Benefits and Pension Monitor.
She said the gender health gap affects women’s participation in the workplace, noting that 60 percent of working women believe health issues impact their careers and only 37 percent feel their employer provides adequate health support. “It’s time to change that.”
Eric Tse, general manager of Biogen Canada, told The Canadian Press he hopes Zurzuvae will be available in Canada in the first few months of next year and that the two‑week course costs about US$16,000.
He said Biogen will work with private insurers on coverage and may “eventually” negotiate with public drug plans, adding the company is setting up a “patient support program” for people without private coverage who cannot pay out of pocket, according to The Canadian Press.
In the United States, early access was complicated by utilization controls and distribution rules.
Some insurers initially required patients to try other antidepressants first or get prescriptions from psychiatrists, even though that went beyond FDA requirements, The New York Times reported.
The drug has a list price of about US$15,900 there and is available only through specialty pharmacies that require additional insurance and delivery verification.
Joy Burkhard of the Policy Center for Maternal Mental Health said most insurers and Medicaid have since eased the strictest barriers, but some extra steps remain, The New York Times reported.
What the drug does
Zuranolone is a synthetic version of allopregnanolone, a metabolite of progesterone that fluctuates with pregnancy and acts on gamma‑aminobutyric acid (GABA) receptors involved in mood regulation, reported The Canadian Press.
Hormonal shifts around late pregnancy and childbirth have been linked to postpartum depression, said Crystal Clark, Canada Research Chair in reproductive mental health and psychiatrist at Women’s College Hospital in Toronto.
Traditional selective serotonin reuptake inhibitor (SSRI) antidepressants are commonly used in postpartum depression but work more slowly and typically require long‑term use, Clark told The Canadian Press.
Zurzuvae is designed as a single, fast‑acting, 14‑day course.
Clark said the medication is recommended for moderate to severe postpartum depression, with severity based on impairment in daily functioning.
Symptoms can include low mood or severe mood swings, significant anxiety or panic attacks, intense irritability and anger, feelings of worthlessness, shame or guilt, difficulty bonding with the baby, and overwhelming fatigue beyond normal new‑parent sleep loss, according to The Canadian Press.
Evidence and safety
Health Canada conducted a “thorough review” of Biogen’s data and concluded “that the drug meets all criteria for safety, effectiveness and quality, and that its benefits outweigh its risks when used as intended,” The Canadian Press reported.
A randomized trial of 196 women with severe postpartum depression found “significant improvements” on the Hamilton Rating Scale for Depression among those who took zuranolone versus placebo, with some improving as early as three days; symptoms remained reduced at 45 days.
Clark noted that longer‑term durability beyond that point is still unclear but said patients in the United States “are doing well” on the drug.
The FDA said Zurzuvae’s efficacy was demonstrated in two randomized, double‑blind, placebo‑controlled multicentre studies of women whose symptoms started in the third trimester or within four weeks after delivery.
Patients who took Zurzuvae or an equivalent zuranolone product for 14 days had significantly greater improvement on the 17‑item Hamilton depression rating scale at Day 15 than those on placebo, and the effect persisted to Day 42, four weeks after the last dose, according to the FDA.
The FDA warns that Zurzuvae can impair driving and other hazardous activities and says patients may not recognize their own impairment, advising them not to drive or operate heavy machinery for at least 12 hours after a dose.
Common side‑effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis and urinary tract infection.
The label also warns of possible suicidal thoughts and behaviour and potential fetal harm, and advises women to use effective contraception while taking the drug and for one week afterward.
In Canadian trial data, the most frequent side‑effects were drowsiness, dizziness, sedation and headache.
Clark told The Canadian Press that women should not breastfeed while taking zuranolone until more research is available on infant safety and suggested having another adult help with baby care during the first days of treatment because of possible drowsiness.
Celebrity spotlight and postpartum anxiety
Business Insider reported that Jennifer Lawrence experienced postpartum anxiety after her second child, saying, “I just thought every time he was sleeping he was dead,” and, “I thought he cried because he didn't like his life, or me, or his family. I thought I was doing everything wrong, and that I would ruin my children.”
She told The New Yorker cited in the same article, that she even asked ChatGPT for breastfeeding advice and was struck when the chatbot told her, “You're doing the most amazing thing for your baby,” and, “You're such a loving mother.”
Business Insider said Lawrence took Zurzuvae, approved by the FDA in 2023 for postpartum depression, and credited it with easing her symptoms.
She described her postpartum experiences as “extremely isolating” and said, “The truth is extreme anxiety, and extreme depression, is isolating no matter where you are. You feel like an alien,” according to Business Insider.
